Delivering 25% of Total Enrollment for a Phase 3 Rare Disease Trial

Science 37 was the top enrolling site, contributing 25% of all randomized patients nationwide. Through its Direct-to-Patient Site, which proved well-suited for this hard-to-enroll, rare disease population, including pediatric patients, Science 37 achieved a 94% patient retention rate.